May 2 |
Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity
|
May 1 |
Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare
|
May 1 |
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
|
Apr 22 |
ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months
|
Feb 22 |
Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
|
Jan 24 |
ELEVAI LABS announces issuance of patent
|
Jan 24 |
ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office
|
Jan 23 |
Top 4 Defensive Stocks That Could Lead To Your Biggest Gains In January
|
Jan 17 |
ELEVAI LABS reports preliminary total net revenue for 2023 of over $1.635M
|
Jan 17 |
ELAB, KIND and RLX among pre-market losers
|